Navigation Links
HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective
Date:12/4/2008

DALLAS Dec. 4, 2008 Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicenter study.

Results of the 3-year study, called the HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial, appear in today's issue of The New England Journal of Medicine. The researchers found no difference in the rate of progression of liver disease among patients who received interferon and those who did not.

"It wasn't that there was an insignificant difference; there was absolutely no difference whatsoever in the progression to cirrhosis and other disease complications," said Dr. William M. Lee, professor of internal medicine at UT Southwestern and a principal investigator for the study. "It is a negative study but an important one."

Dr. Lee said physicians should not expect any benefit from the long-term use of interferon by itself in slowing disease progression. By contrast, use of interferon with other drugs such as ribavirin can lead to viral eradication, or complete clearance of hepatitis C virus, a result that will "stop the disease in its tracks," Dr. Lee said.

Hepatitis C is a viral infection that causes liver inflammation and can progress over many years to cirrhosis, liver cancer, liver failure and death. The disease affects more than 3 million people in the United States and 170 million people worldwide. It is the most common reason for liver transplantation in the U.S.

There is no vaccine to prevent hepatitis C virus infection. The combination of interferon and ribavirin works for about 40 percent to 50 percent of people with the virus, while the other 50 percent to 60 percent of patients will continue to progress to later states of liver disease, Dr. Lee said.

In additio
'/>"/>

Contact: LaKisha Ladson
lakisha.ladson@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Children Tell Researchers: Well Get Fit if Its Fun
2. Researchers: Ban on fast food TV advertising would reverse childhood obesity trends
3. Researchers: Program discourages HIV transmission in Russia
4. Attacks against medical researchers: Time to take a stand
5. Mayo Clinic researchers: Insulin-boosting medication does not impair ability to survive heart attack
6. Mayo researchers: complementary therapies help patients recover after heart surgery
7. OHSU researchers: Surgery, radiation gives early survival advantage in bile duct cancer
8. Interferon needed for cells to remember how to defeat a virus, UT Southwestern researchers report
9. Only Half of MS Patients Respond to Interferon Therapy
10. Interferon Reduces, Eliminates Viral Infections in Heart Failure Patients
11. Study shows that high-dose, high-frequency interferon produces no additional benefit

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective
HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective
(Date:12/4/2009)...Health Reform Bills Will Increase Deficit ,, WA...e claims that the pending health reform bills aren...icare savings take effect, Congress has allowed th...n the past two decades to take effect and produce ...n Budget and Policy Priorities shows. ,, The an...
(Date:12/4/2009)...oss can be an effective way to improve moderate to...dical university Karolinska Institutet report. Tho...enefited most from weight loss. , "Our findings...tment strategy for sleep apnoea in obese men," say...in the study. , Sleep apnoea the temporary cess...
(Date:12/4/2009)... Mouthguard (PPM) - certified Dr. Nassery serves l...tment and options , Miami...ist Dr. H.A. Nassery contributes to local athleti...s in young athletes and offering the Pure Power Mo...d treated Ashley Kimmel, a student at Miami Countr...
(Date:12/4/2009)...gh to recommend its use, experts say , , ...ents, glaucoma patients and others can benefit fro...that it can help multiple sclerosis (MS) patients ...llmark of the debilitating autoimmune disease. ,... appears to be comprehensive, and should be given ...
(Date:12/4/2009)...ON, Dec. 4 AES Annual Me...YBX ) announced today that Vagus Nerve Stimulatio...e medical device for the treatment of refractory e...he American Epilepsy Society,s (AES) Annual Meeti...tion Center in Boston, Massachusetts. ,, Robe...
Breaking Medicine News(10 mins):Health News:Congress Has Allowed Most Previous Medicare Cuts to Take Effect, New Study Shows 2Health News:Congress Has Allowed Most Previous Medicare Cuts to Take Effect, New Study Shows 3Health News:Congress Has Allowed Most Previous Medicare Cuts to Take Effect, New Study Shows 4Health News:Weight-loss proves effective cure for sleep apnea 2Health News:Weight-loss proves effective cure for sleep apnea 3Health News:Miami Dentist Dr. H.A. Nassery Treats Local Teen Golf Star and Helps Improve Her Performance 2Health News:Review Finds Marijuana May Help MS Patients 2Health News:Review Finds Marijuana May Help MS Patients 3Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 3
...s, gene therapy has given rise not only to high ex...cerns regarding health risks//. Since the German R...t (DFG) issued its first memorandum in 1995; this ..., makes it clear that gene therapy already shows s...
...nds that 95 percent of Americans have pre marital ...ing new as American men //and women as far back as...chers are disappointed that spending hundreds of m... if the programs don't stop teens from having prem...
...ychedelic mushrooms, also called magic mushrooms c...mpulsion disorder (OCD), according to a study// by...ain psychedelic substances like psilocybin, psiloc...the safety of administrating psilocybin, though it...
...ificantly cut down use of illicit drugs, but have ...erous, say experts. // Dr. Grant Mitchell, ch... Center, in Mount Kisco, N.Y said, "This doesn't s... need to go out and procure illicit drugs." ...
... reported a very interesting finding made by a gro...e researchers found that obese people seem to hav... that helps to digest food well .Slim folks seem ...en down and the bacteria in obese people seem mor...
...how delay the greying process continues with gusto... eons now. Youthfulness always pouts with tantalis...sburgh is that the secret is enmeshed in DNA. If t...tself to rejuvenate and repair itself. This was re...
Other Medicine News:Health News:Gene Therapy for Hereditary Immunodeficiency Diseases 2Health News:Intestinal Bacteria Blamed for Rotund Figures 2Health News:Clues to Allay Aging 2
(Date:12/3/2009)... , KALAMAZOO, Mich., Dec. 3 /PRNewswire-FirstCa...d today that its Board of Directors has authorized...ts common stock. The manner, timing and amount of... management based on their evaluation of market co...e subject to regulatory considerations. Purchases...
(Date:12/3/2009)... , BEDFORD, Mass., Dec. 3 Micro...ant systems, today announced it has been named a 2.... ,, The company was selected for pioneering ..., responsive implants designed to bridge the gap b...PS, technologies have broad applicability, from ,r...
(Date:12/3/2009)... , MAPLE GROVE, Minn., Dec. 3 /PRNewswire/ ... the next phase of its strategic plan for central ...d release topiramate), an internally developed pro...ng developed with Upsher-Smith,s proprietary formu...cal trial in early 2010 for the adjunctive treatme...
Breaking Medicine Technology:Stryker Announces $750 Million Share Repurchase Program and Declares a $0.15 Per Share Quarterly Dividend 2MicroCHIPS Named 2010 Technology Pioneer by World Economic Forum 2Upsher-Smith Announces Milestone in Development of CNS Strategy 2Comic Strip Delivers Message on Diabetes Health 50439 1Comic Strip Delivers Message on Diabetes Health 50439 2Comic Strip Delivers Message on Diabetes Health 50439 3Creighton University St Josephs Hospital and Medical Center Announce New School of Medicine Campus in Phoenix 50434 1Creighton University St Josephs Hospital and Medical Center Announce New School of Medicine Campus in Phoenix 50434 2Damon Runyon Cancer Research Foundation awards 242 7M to 7 top young clinical investigators 50431 1Damon Runyon Cancer Research Foundation awards 242 7M to 7 top young clinical investigators 50431 2Damon Runyon Cancer Research Foundation awards 242 7M to 7 top young clinical investigators 50431 3Damon Runyon Cancer Research Foundation awards 242 7M to 7 top young clinical investigators 50431 4
.../ -- Interim results from,a multicenter trial inve...l using CellCept(R) (mycophenolate mofetil) were p... and other Spare the,Nephron (STN) trials in kidne...prevent rejection without damaging kidneys. , As t...finding,that older therapies such as steroids and ...
...e-FirstCall/ -- ISTA,Pharmaceuticals, Inc., today ... its U.S. Phase II/III clinical study of bepotasti...he study evaluated two,concentrations of bepotasti...mary endpoints of the study were the assessment of...ng and redness.,The preliminary results of the stu...
Other Medicine Technology:Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function 2Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function 3Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function 4Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function 5ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 2ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 3ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 4ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 5
...de; is a full-featured healthcare bed system provi... for the care and management of larger patients, ...lbs. ,Large patients at risk for pressure ulcers, ...0 lbs. (including accessories), ,PRECAUTION: ,Sid...
EC+ Extra Care Bariatric Bed
Triflex™ II Bariatric Bed
Tri-Flex I System
Medicine Products: